Doseology Uplists to OTCQB, Expanding U.S. Investor Access to Oral Stimulant Pouches
Event summary
- Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) began trading on the OTCQB Venture Market on March 11, 2026, under the symbol DOSEF.
- The company appointed Larry Latowsky as Executive Chairman of the Board to support compliance with new market standards.
- Doseology issued 75,000 pre-funded warrants to Joseph Mimran & Associates Inc. as part of the acquisition of the 'Feed That Brain' division.
- Additional issuances of 75,000 pre-funded warrants are due on the one-year and eighteen-month anniversaries of the acquisition closing.
The big picture
Doseology's uplisting to the OTCQB Venture Market is a strategic move to tap into the largest capital market and one of the most important consumer markets for modern oral stimulant products. The company is positioning itself as an early pure-play public company in this emerging category, competing with global players like Philip Morris International and British American Tobacco. The oral pouch category is experiencing strong global growth as consumers seek smoke-free and discreet delivery formats, making Doseology's platform approach to product development and direct-to-consumer distribution a key differentiator.
What we're watching
- Market Penetration
- How Doseology's OTCQB listing will affect its ability to attract U.S. investors and scale its operations in the oral stimulant pouch category.
- Regulatory Compliance
- Whether the company can maintain the higher transparency and governance standards required by the OTCQB Venture Market.
- Product Innovation
- The pace at which Doseology can develop proprietary stimulant technologies and intellectual property to differentiate itself in the competitive oral pouch market.
Related topics